BridgeMD
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN )
EU CTIS ID: 2025-522631-34-00
What this study is testing
To demonstrate that orforglipron once daily maximum tolerated dose (MTD) is superior to placebo for change in the WOMAC pain subscale score.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have obesity or overweight
- Have tried to lose weight through diet at least once but were not successful
- Have osteoarthritis of the knee
- Be willing to stop certain pain medications during the entire study
You likely can't join if
- Have taken a glucagon-like peptide-1 (GLP-1) medication within 180 days or other weight loss medications in the 90 days before screening.
- Have type 1 or type 2 diabetes or another type of diabetes
- Be taking a medicine to lower blood sugar in the 90 days before screening.
- Have had a recent heart attack, stroke or other heart event in the 90 days before screening
- Have had surgery for obesity or plan to have one in the next 18 months
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- China
- Japan
- Mexico
- United States
- India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; China; Japan; Mexico; United States; India. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.